ALTITUDE: defining a ceiling for blockade of the renin-angiotensin system?

Affiliations

¹ The George Institute for Global Health, University of Sydney, Sydney 2050, NSW, Australia; Concord Hospital, Sydney, NSW, Australia. Electronic address: mgallagher@georgeinstitute.org.au.
² The George Institute for Global Health, University of Sydney, Sydney 2050, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia.

Comment

Martin Gallagher et al. Lancet Diabetes Endocrinol. 2016 Apr.

. 2016 Apr;4(4):289-90.

doi: 10.1016/S2213-8587(15)00518-5. Epub 2016 Jan 14.

¹ The George Institute for Global Health, University of Sydney, Sydney 2050, NSW, Australia; Concord Hospital, Sydney, NSW, Australia. Electronic address: mgallagher@georgeinstitute.org.au.
² The George Institute for Global Health, University of Sydney, Sydney 2050, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia.

No abstract available

Comment on

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D. Heerspink HJ, et al. Lancet Diabetes Endocrinol. 2016 Apr;4(4):309-17. doi: 10.1016/S2213-8587(15)00469-6. Epub 2016 Jan 14. Lancet Diabetes Endocrinol. 2016. PMID: 26774608 Clinical Trial.